Company Analysis Arena Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (93.96 $) is less than fair price (168.98 $)
- The stock's return over the last year (0%) is higher than the sector average (-34.6%).
- Current debt level 5.25% is below 100% and has decreased over 5 years from 7.67%.
- The company's current efficiency (ROE=-70.3%) is higher than the sector average (ROE=-80.97%)
Disadvantages
- Dividends (0%) are below the sector average (1.23%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Arena Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -6% | -0.1% | 1.7% |
| 90 days | -6% | -42% | 6.1% |
| 1 year | 0% | -34.6% | 31.4% |
ARNA vs Sector: Arena Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 34.6% over the past year.
ARNA vs Market: Arena Pharmaceuticals, Inc. has significantly underperformed the market by -31.4% over the past year.
Stable price: ARNA is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ARNA with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (93.96 $) is lower than the fair price (168.98 $).
Price significantly below the fair price: The current price (93.96 $) is 79.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (57.99).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (47.35).
4.3. P/BV
P/BV vs Sector: The company's P/BV (9.16) is lower than that of the sector as a whole (9.41).
P/BV vs Market: The company's P/BV (9.16) is lower than that of the market as a whole (22.57).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (112540) is higher than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (112540) is higher than that of the market as a whole (15.08).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.3315) is lower than that of the sector as a whole (17.46).
EV/Ebitda vs Market: The company's EV/Ebitda (0.3315) is lower than that of the market as a whole (22.75).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -51.01% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-51.01%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-14.25%).
5.4. ROE
ROE vs Sector: The company's ROE (-70.3%) is higher than that of the sector as a whole (-80.97%).
ROE vs Market: The company's ROE (-70.3%) is lower than that of the market as a whole (16.86%).
5.5. ROA
ROA vs Sector: The company's ROA (-62.41%) is lower than that of the sector as a whole (6.65%).
ROA vs Market: The company's ROA (-62.41%) is lower than that of the market as a whole (6.56%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.23%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
